The Medicines and Healthcare products Regulatory Agency said on 15 May 2026 that it had approved beremagene geperpavec, marketed as Vyjuvek, for the treatment of wounds in patients with dystrophic epidermolysis bullosa. The licence covers use from birth onward, creating a new authorised option in a rare inherited skin disorder. In regulatory terms, this is a medicines approval rather than a broad policy reset. Even so, for a condition with limited treatment options, a narrowly framed licensing decision can carry real weight for patients, clinicians and specialist services.
Dystrophic epidermolysis bullosa, often shortened to DEB, is a rare genetic condition in which the skin is unusually fragile and prone to blistering. The MHRA said the disorder is linked to a fault in a gene responsible for holding skin layers together, which helps explain why recurrent wounds are such a persistent feature of the disease. The agency said Vyjuvek works by delivering copies of the affected gene into cells in the wound to support healing. It is supplied as a gel and applied directly to wounds. The MHRA also made clear that the modified virus and genetic material used in the medicine do not alter the patient's DNA.
The clinical evidence cited in the MHRA notice comes from a study of 31 patients aged 1 to 44 years with dystrophic epidermolysis bullosa. At six months, 67 per cent of wounds treated with beremagene geperpavec were completely healed, compared with 22 per cent of wounds treated with placebo. For a rare disease population, those figures give a concrete benchmark for the medicine's observed effect on wound closure. They do not remove the need for careful clinical oversight, but they do show why the regulator concluded that the product met the threshold for approval.
Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the decision provides a new treatment option for patients living with dystrophic epidermolysis bullosa. He also said the regulator would continue to monitor the safety and effectiveness of beremagene geperpavec as use becomes more widespread. That point matters because approval is only one stage in the medicines system. The MHRA said the full list of reported side effects is set out in Section 4 of the Patient Information Leaflet and the Summary of Product Characteristics, both of which are due to be published on the MHRA Products website within seven days of the approval date.
The approval was granted to Krystal Biotech Netherlands, B.V. The MHRA also said the product was submitted and approved through the International Recognition Procedure. In practical terms, that route allows the regulator to draw on a recognised international assessment as part of the UK review, while still issuing its own national decision. For policy readers, that makes this more than a single product announcement. It is also a live example of how the MHRA is using recognition-based routes for specialist medicines within the UK licensing system.
For patients and families, the immediate significance is straightforward: a medicine specifically approved for DEB wound treatment now has UK regulatory clearance from birth onward. For clinicians, the next step is likely to be close reading of the published product information, which will set out administration details, safety information and the formal licensed indication. Because Vyjuvek is applied directly to wounds as a gel, the approval concerns day-to-day wound treatment rather than a one-off intervention. That practical feature will matter to specialist dermatology, paediatric and rare disease teams considering how the product may fit alongside existing care.
For health policy watchers, the announcement is a reminder that rare disease progress often arrives through highly technical regulatory decisions rather than large system-wide reforms. A licence for a single product can still be important because it establishes the lawful basis for use, defines the approved indication and creates a framework for ongoing safety monitoring. The MHRA notice is tightly drawn and does not present Vyjuvek as a cure for dystrophic epidermolysis bullosa. What it does confirm is that, as of 15 May 2026, the regulator judged the available evidence sufficient to approve beremagene geperpavec for wound treatment in this patient group, including from birth.